Advances in leishmaniasis immunopathogenesis

Acta Medica Mediterranea

Volumn 27, Issue 1, 2011, Pages 7-16

  Mansueto, Pasquale ^a   Vitale, Giustina ^a   Seidita, Aurelio ^a   Guarneri, Francesco Paolo ^a   Pepe, Ilenia ^a   Rinollo, Carmelina ^a   Di Rosa, Salvatore ^b   Rini, Giovambattista ^a   Cillari, Enrico ^b   Di Fede, Gaetana ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Azienda Ospedaliera Ospedali Riuniti 'Villa Sofia Cervello'   (Italy)

Author keywords

Apoptosis; Chemokines; Citokines; Cutaneous leishmaniasis; Visceral leishmaniasis

Indexed keywords

CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CYTOKINE; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; LEISHMANIA VACCINE; MONOCYTE CHEMOTACTIC PROTEIN 1;

AMASTIGOTE; APOPTOSIS; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CLINICAL ASSESSMENT; CLINICAL FEATURE; DISEASE COURSE; EXPLORATORY BEHAVIOR; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; INNATE IMMUNITY; LEISHMANIA; LEISHMANIA DONOVANI; LEISHMANIASIS; LYMPHOCYTE FUNCTION; MACROPHAGE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PUBLIC HEALTH PROBLEM; REGULATORY T LYMPHOCYTE; SKIN LEISHMANIASIS; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL; VISCERAL LEISHMANIASIS;

EID: 79960629385     PISSN: 03936384     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Dantas-Torres F, Brandao-Filho SP. Visceral leishmaniasis in Brazil: revisiting paradigms of epidemiology and control. Rev Inst Med Trop Sao Paulo 2006; 48: 151-6.
2. Bern C, Chowdhury R. The epidemiology of visceral leishmaniasis in Bangladesh: prospects for improved control. Indian J Med Res 2006; 123: 275-88.
3. Steffen R, Rickenbach M, Wilhelm U, Helminger A, Schar M. Health problems after travel to developing countries. J Infect Dis 1987; 156: 84-91.
4. Murray HW, Berman JD, Davies CR and Saravia NG. Advances in leishmaniasis. Lancet 2005; 366: 1561-77.
5. Croft SL, Vivas L and Brooker S. Recent advances in research and control of malaria, leishmaniasis, trypanosomiasis and schistosomiasis. East Mediterr Health J 2003; 9: 518-33.
6. Thomaz-Soccol V, Lanotte G, Rioux J A, Pratlong F, Martini-Dumas A and Serres E. Phylogenetic taxonomy of New World Leishmania. Ann Parasitol Hum Comp 1993; 68: 104-6.
7. Gramiccia M And Gradoni L. The current status of zoonotic leishmaniases and approaches to disease control. Int J Parasitol 2005; 35: 1169-80.
8. Bates PA and Rogers ME. New insights into the developmental biology and transmission mechanisms of Leishmania. Curr Mol Med 2004; 4: 601-9.
9. Colmenares M, Kar S, Goldsmith-Pestana K and McMahon-Pratt D. Mechanisms of pathogenesis: differences amongst Leishmania species. Trans R Soc Trop Med Hyg 2002; 96: S3-7.
10. Gumy A, Louis JA and Launois P. The murine model of infection with Leishmania major and its importance for the deciphering of mechanisms underlying differences in Th cell differentiation in mice from different genetic backgrounds. Int J Parasitol 2004; 34: 433.
11. Louis JA, Gumy A, Voigt H, Launois P and Rocken M. The use of the murine model of infection with Leishmania major to reveal the antagonistic effects that IL-4 can exert on T helper cell development and demonstrate that these opposite effects depend upon the nature of the cells targeted for IL-4 signaling. Pathol Biol 2003; 51: 71.
12. Vannier-Santos MA, Martiny A and de Souza W. Cell biology of Leishmania spp.: invading and evading. Curr Pharm Des 2002; 8: 297.
13. McSorley S, Proudfoot L, O'Donnell CA and Liew FY. Immunology of murine leishmaniasis. Clin Dermatol 1996; 14: 451.
14. Barbieri CL. Immunology of canine leishmaniasis. Parasite Immunol. 2006; 28: 329.
15. Roberts MT. Current understandings on the immunology of leishmaniasis and recent developments in prevention and treatment. Br Med Bull 2006; 75-76: 115-30.
16. Steigerwald M and Moll H. Leishmania major modulates chemokine and chemokine receptor expression by dendritic cells and affects their migratory capacity. Infect Immun 2005; 73: 2564-7.
17. Ritter U and Moll H. Monocyte chemotactic protein-1 stimulates the killing of Leishmania major by human monocytes, acts synergistically with IFN-gamma and is antagonized by IL-4. Eur J Immunol 2000; 30: 3111-20.
18. Constantinescu CS, Hondowicz BD, Elloso MM, Wysocka M, Trinchieri G and Scott P. The role of IL-12 in the maintenance of an established Th1 immune response in experimental leishmaniasis. Eur J Immunol 1998; 28: 2227-33.
19. Kemp M, Kurtzhals JA, Bendtzen K, Poulsen LK, Hansen MB, Koech DK, Kharazmi A and Theander TG. Leishmania donovani-reactive Th1- and Th2-like T-cell clones from individuals who have recovered from visceral leishmaniasis. Infect Immun 1993; 61: 1069-73.
20. Chtanova T and Mackay CR. T cell effector subsets: extending the Th1/Th2 paradigm. Adv Immunol 2001; 78: 233-66.
21. Bacellar O, D'Oliveira A Jr, Jeronimo S and Carvalho EM. IL-10 and IL-12 are the main regulatory cytokines in visceral leishmaniasis. Cytokine 2000; 12: 1228-31.
22. Murray HW, Tsai CW, Liu J and Ma X. Responses to Leishmania donovani in mice deficient in interleukin-12 (IL-12), IL-12/IL-23, or IL-18. Infect Immun 2006; 74: 4370-4.
23. Artis D, Johnson LM, Joyce K, Saris C, Villarino A, Hunter CA and Scott P. Cutting edge: early IL-4 production governs the requirement for IL-27-WSX-1 signaling in the development of protective Th1 cytokine responses following Leishmania major infection. J Immunol 2004; 172: 4672-5.
24. Elloso MM and Scott P. Expression and contribution of B7-1 (CD80) and B7-2 (CD86) in the early immune response to Leishmania major infection. J Immunol 1999; 162: 6708-15.
25. Padigel UM and Farrell JP. CD40-CD40 ligand costimulation is not required for initiation and maintenance of a Th1-type response to Leishmania major infection. Infect Immun 2003; 71: 1389-95.
26. Holzmuller P, Bras-Goncalves R and Lemesre JL. Phenotypical characteristics, biochemical pathways, molecular targets and putative role of nitric oxidemediated programmed cell death in Leishmania. Parasitology 2006; 132: S19-32.
27. Liew FY, Wei XQ and Proudfoot L. Cytokines and nitric oxide as effector molecules against parasitic infections. Phil Trans R Soc Lond B 1997; 352: 1311-5.
28. Al-Zamel F, Al-Shammary FJ, El-Shewemi S and Soliman R. Enhancement of leishmanicidal activity of human macrophages against Leishmania major and Leishmania donovani infection using recombinant human granulocyte macrophage colony stimulating factor. Zentralbl Bakteriol 1996; 285: 92-105.
29. Nunes MP, Cysne-Finkelstein L, Monteiro BC, de Souza DM, Gomes NA and DosReis GA. CD40 signaling induces reciprocal outcomes in Leishmania-infected macrophages; roles of host genotype and cytokine milieu. Microbes Infect 2005; 7: 78-85.
30. Eidsmo L, Nylen S, Khamesipour A, Hedblad MA, Chiodi F and Akuffo H. The contribution of the Fas/FasL apoptotic pathway in ulcer formation during Leishmania major-induced cutaneous Leishmaniasis. Am J Pathol 2005; 166: 1099-108.
31. Potestio M, D'Agostino P, Romano GC, Milano S, Ferlazzo V, Aquino A, Di Bella G, Caruso R, Gambino G, Vitale G, Mansueto S and Cillari E. CD4+ CCR5+ and CD4+ CCR3+ lymphocyte subset and monocyte apoptosis in patients with acute visceral leishmaniasis. Immunology 2004; 113: 260-8.
32. Belkaid Y. The role of CD4(+)CD25(+) regulatory T cells in Leishmania infection. Expert Opin Biol Ther 2003; 3: 875-85.
33. Kariminia A, Bourreau E, Pascalis H, Couppie P, Sainte-Marie D, Tacchini-Cottier F and Launois P. Transforming growth factor beta 1 production by CD4+ CD25+ regulatory T cells in peripheral blood mononuclear cells from healthy subjects stimulated with Leishmania guyanensis. Infect Immun 2005; 73: 5908-14.
34. Aguilar-Torrentera F and Carlier Y. Immunological factors governing resistance and susceptibility of mice to Leishmania major infection. Rev Latinoam Microbiol 2001; 43: 135-42.
35. Sacks D and Noben-Trauth N. The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2002; 2: 845-58.
36. Noben-Trauth N, Lira R, Nagase H, Paul WE and Sacks DL. The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major. J Immunol 2003; 170: 5152-8.
37. Matthews DJ, Emson CL, McKenzie GJ, Jolin HE, Blackwell JM and McKenzie AN. IL-13 is a susceptibility factor for Leishmania major infection. J Immunol 2000; 164: 1458-62.
38. Li J, Hunter CA and Farrell JP. Anti-TGF-beta treatment promotes rapid healing of Leishmania major infection in mice by enhancing in vivo nitric oxide production. J Immunol 1999; 162: 974-9.
39. Shankar A H and Titus R G. The influence of antigenpresenting cell type and interferon-gamma on priming and cytokine secretion of Leishmania major-specific T cells. J Infect Dis 1997; 175: 151-7.
40. Chakir H, Campos-Neto A, Mojibian M and Webb JR. IL-12Rbeta2-deficient mice of a genetically resistant background are susceptible to Leishmania major infection and develop a parasite-specific Th2 immune response. Microbes Infect 2003; 5: 241-9.
41. Alexander J and Bryson K. T helper (h)1/Th2 and Leishmania: paradox rather than paradigm. Immunol Lett 2005; 99: 17-23.
42. Denise H, McNeil K, Brooks DR, Alexander J, Coombs GH and Mottram JC. Expression of multiple CPB genes encoding cysteine proteases is required for Leishmania mexicana virulence in vivo. Infect Immun2003; 71: 3190-5.
43. Ueda-Nakamura T, da Conceicao Rocha Sampaio M, Cunha-e-Silva NL, Traub-Cseko YM and de Souza W. Expression and processing of megasome cysteine proteinases during Leishmania amazonensis differentiation. Parasitol Res 2002; 88: 332-7.
44. Cameron P, McGachy A, Anderson M, Paul A, Coombs GH, Mottram JC, Alexander J and Plevin R. Inhibition of lipopolysaccharide-induced macrophage IL-12 production by Leishmania mexicana amastigotes: the role of cysteine peptidases and the NF-kappaB signaling pathway. J Immunol 2004; 173: 3297-304.
45. Kaye PM, Curry AJ and Blackwell JM. Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccineinduced rate of cure in murine visceral leishmaniasis. J Immunol 1991; 146: 2763-70.
46. Cillari E, Vitale G, Arcoleo F, D'Agostino P, Mocciaro C, Gambino G, Malta R, Stassi G, Giordano C and Milano S. In vivo and in vitro cytokine profiles and mononuclear cell subsets in Sicilian patients with active visceral leishmaniasis. Cytokine 1995; 7: 740-5.
47. Ansari NA, Saluja S and Salotra P. Elevated levels of interferon-gamma, interleukin-10, and interleukin-6 during active disease in Indian kala azar. Clin Immunol 2006; 119: 339-45.
48. Vitale G, Reina G, Mansueto S, Malta R, Gambino G, Mocciaro C, D'Agostino R, Dieli M and Cillari E. The significance of serum soluble IL-2 receptor as a marker for active visceral leishmaniasis in Sicilian patients. Clin Exp Immunol 1992; 90: 219-22.
49. Cillari E, Liew FY, Lo Campo P, Milano S, Mansueto S and Salerno A. Suppression of IL-2 production by cryopreserved peripheral blood mononuclear cells from patients with active visceral leishmaniasis in Sicily. J Immunol 1988; 140: 2721-6.
50. Cillari E, Milano S, Dieli M, Maltese E, Di Rosa S, Mansueto S, Salerno A and Liew FY. Reduction in the number of UCHL-1+ cells and IL-2 production in the peripheral blood of patients with visceral leishmaniasis. J Immunol 1991; 146: 1026-30.
51. Carvalho EM, Badaro R, Reed SG, Jones TC and Johnson WD. Absence of gamma interferon and interleukin-2 production during active visceral leishmaniasis. J Clin Invest 1985; 76: 2066-9.
52. Ghalib HW, Piuvezam MR, Skeiky YA, Siddig M, Hashim FA, el-Hassan AM, Russo DM and Reed SG. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 1993; 92: 324-9.
53. Carvalho EM, Bacelar O, Brownell CE, Regis T, Coffman RL and Reed SG. Restoration of IFN-gamma production and lymphocyte proliferation in visceral leishmaniasis. J Immunol 1994; 152: 5949-56.
54. Ghalib HW, Whittle JA, Kubin M, Hashim FA, el-Hassan AM, Grabstein KH, Trinchieri G and Reed SG. IL-12 enhances Th1-type responses in human Leishmania donovani infections. J Immunol 1995; 154: 4623-9.
55. Kurkjian KM, Mahmutovic AJ, Kellar KL, Haque R, Bern C and Secor WE. Multiplex analysis of circulating cytokines in the sera of patients with different clinical forms of visceral leishmaniasis. Cytometry A 2006; 69: 353-8.
56. Kemp M, Theander TG and Kharazmi A. The contrasting roles of CD4+ T cells in intracellular infections in humans: leishmaniasis as an example. Immunol Today 1997; 17: 13-6.
57. Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997; 18: 263-6.
58. Woldmann TA and Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 1999; 17: 19-49.
59. Lauwerys BR, Garot N, Renauld JC and Houssiau FA. Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18. J Immunol 2000; 165: 1847-53.
60. Loza MJ, Zamai L, Azzoni L, Rosati E and Perussia B. Expression of type 1 (interferon gamma) and type 2 (interleukin-13, interleukin-5) cytokines at distinct stages of natural killer cell differentiation from progenitor cells. Blood 2002; 99: 1273-81.
61. Milano S, Di Bella G, D'Agostino P, Barbera C, Caruso R, La Rosa M, Ferlazzo V, Vitale G, La Russa C, Gambino G, Chifari N, Mansueto S and Cillari E. IL-15 in human visceral leishmaniasis caused by Leishmania infantum. Clin Exp Immunol 2002; 127: 360-5.
62. D'Agostino P, Milano S, Arcoleo F, Di Bella G, La Rosa M, Ferlazzo V, Caruso R, Chifari N, Vitale G, Mansueto S and Cillari E. Interleukin-15, as interferongamma, induces the killing of Leishmania infantum in phorbol-myristate-acetate-activated macrophages increasing interleukin-12. Scand. J Immunol 2004; 60: 609-14.
63. Lehmann J, Enssle KH, Lehmann I, Emmendorfer A and Lohmann-Matthes ML. The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice. J Interferon Cytokine Res 2000; 20: 63-77.
64. Satoskar A, Bluethmann H and Alexander J. Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection. Infect Immun 1995; 63: 4894-9.
65. Stager S, Alexander J, Carter KC, Brombacher F and Kaye PM. Both interleukin-4 (IL-4) and IL-4 receptor alpha signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity. Infect Immun 2003; 71: 4804-7.
66. Wilson ME, Young BM, Davidson BL, Mente KA and McGowan SE. The importance of TGF-beta in murine visceral leishmaniasis. J Immunol 1998; 161: 6148-55.
67. Murray HW, Flanders KC, Donaldson DD, Sypek JP, Gotwals PJ, Liu J and Ma X. Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis. Infect Immun 2005; 73: 3903-11.
68. Gollob KJ, Antonelli LR and Dutra WO. Insights into CD4+ memory T cells following Leishmania infection. Trends Parasitol 2005; 21: 347-50.
69. Hailu A, van Baarle D, Knol GJ, Berhe N, Miedema F and Kager PA. T cell subset and cytokine profiles in human visceral leishmaniasis during active and asymptomatic or sub-clinical infection with Leishmania donovani. Clin Immunol 2005; 117: 182-91.
70. Estaquier J, Idziorek T, Zou W, Emilie D, Farber CM, Bourez JM and Ameisen JC. T helper type 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)-mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons. J Exp Med 1995; 182: 1759-67.
71. Dockrell DH. Apoptotic cell death in the pathogenesis of infectious diseases. J Infect 2001; 42: 227-34.
72. Sereti I, Herpin B, Metcalf JA, Stevens R, Baseler MW, Hallahan CW, Kovacs JA, Davey RT and Lane HC. CD4 T cell expansions are associated with increased apoptosis rates of T lymphocytes during IL-2 cycles in HIV infected patients. AIDS 2001; 15: 1765-75.
73. Das G, Vohra H, Rao K, Saha B and Mishra GC. Leishmania donovani infection of a susceptible host results in CD4+ T-cell apoptosis and decreased Th1 cytokine production. Scand J Immunol 1999; 49: 307-10.
74. Conceicao-Silva F, Hahne M, Schroter M, Louis J and Tschopp J. The resolution of lesions induced by Leishmania major in mice requires a functional Fas (APO-1, CD95) pathway of cytotoxicity. Eur J Immunol 1998; 28: 237-45.
75. Alexander CE, Kaye PM and Engwerda CR. CD95 is required for the early control of parasite burden in the liver of Leishmania donovani-infected mice. Eur J Immunol 2001; 31: 1199-210.
76. Bertho AL, Santiago MA, Da-Cruz AM and Coutinho SG. Detection of early apoptosis and cell death in T CD4+ and CD8+ cells from lesions of patients with localized cutaneous leishmaniasis. Braz J Med Biol Res 2000; 33: 317-25.
77. Tsagozis P, Karagouni E and Dotsika E. Function of CD8+ T lymphocytes in a self-curing mouse model of visceral leishmaniasis. Parasitol Int 2005; 54: 139-46.
78. Tsagozis P, Karagouni E and Dotsika E. CD8(+) T cells with parasite-specific cytotoxic activity and a Tc1 profile of cytokine and chemokine secretion develop in experimental visceral leishmaniasis. Parasite Immunol 2003; 25: 569-79.
79. Sharma MC, Gupta AK, Verma N, Das VN, Saran R and Kar SK. Demonstration of Leishmania parasites in skin lesions of Indian post kala-azar dermal leishmaniasis (PKDL) cases. J Commun 2000; Dis. 32: 67-8.
80. Ismail A, El Hassan AM, Kemp K, Gasim S, Kadaru AE, Moller T, Kharazmi A and Theander TG. Immunopathology of post kala-azar dermal leishmaniasis (PKDL): T-cell phenotypes and cytokine profile. J Pathol 1999; 189: 615-22.